Lucira Health (NASDAQ: LHDX)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-10 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.340 | -0.450 | -0.1100 | ||||
REV | 30.050M | 26.146M | -3.904M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Lucira Health (NASDAQ: LHDX) through any online brokerage.
Other companies in Lucira Health’s space includes: NeuroPace (NASDAQ:NPCE), Second Sight Medical (NASDAQ:EYES), LENSAR (NASDAQ:LNSR), Pro-Dex (NASDAQ:PDEX) and Minerva Surgical (NASDAQ:UTRS).
The latest price target for Lucira Health (NASDAQ: LHDX) was reported by William Blair on Tuesday, May 4, 2021. The analyst firm set a price target for 0.00 expecting LHDX to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
The stock price for Lucira Health (NASDAQ: LHDX) is $2.28 last updated Today at August 17, 2022, 7:49 PM UTC.
There are no upcoming dividends for Lucira Health.
Lucira Health’s Q3 earnings are confirmed for Thursday, November 10, 2022.
There is no upcoming split for Lucira Health.
Lucira Health is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.